Search Videos by Topic or Participant
Browse by Series:

Evolving Role of Stem Cell Transplant in Multiple Myeloma

Panelists:
Published: Monday, Jul 27, 2015


Randomized clinical trial data currently do not support changing therapy if a younger patient with multiple myeloma has achieved a partial response (PR) with induction therapy, states Jatin J. Shah, MD. Changing therapies in this setting could expose the patient to more toxicity and limit the ability to collect stem cells. If a PR is achieved, it could be ideal to move to transplant, Shah suggests. 

Following frontline therapy, patients who do not achieve a deep response with induction therapy and proceed directly to stem cell transplant have similar outcomes to patients who received a second-line non-cross—resistant regimen to drive the response according to a retrospective registry analysis, says Morie A. Gertz, MD. However, data supporting this approach predate induction therapy with novel agents, which makes it difficult to know the optimal way to manage multiple myeloma in this era of newer therapies.

For individuals who achieve a PR with induction therapy, Heather J. Landau, MD, suggests proceeding to stem cell transplant, with the consideration of stem cell mobilization by chemotherapy in individuals who have not had adequate bone marrow cytoreduction. It is important to build clinical trial data to understand what to do now, particularly with a novel agent, says Rafael Fonseca, MD. 

Most patients are achieving better than a PR with the newer drugs, states Noopur Raje, MD. For the time being, stem cells can still be collected and stored for later use at least in the younger population, suggests Raje. To further explore an optimal sequence for novel agents and transplant, a phase II study is assessing carfilzomib, lenalidomide, and dexamethasone before and after stem cell transplant for patients with newly diagnosed multiple myeloma (NCT01816971). This study will help shed light on a possible sequence, Raje suggests. 
Slider Left
Slider Right


Randomized clinical trial data currently do not support changing therapy if a younger patient with multiple myeloma has achieved a partial response (PR) with induction therapy, states Jatin J. Shah, MD. Changing therapies in this setting could expose the patient to more toxicity and limit the ability to collect stem cells. If a PR is achieved, it could be ideal to move to transplant, Shah suggests. 

Following frontline therapy, patients who do not achieve a deep response with induction therapy and proceed directly to stem cell transplant have similar outcomes to patients who received a second-line non-cross—resistant regimen to drive the response according to a retrospective registry analysis, says Morie A. Gertz, MD. However, data supporting this approach predate induction therapy with novel agents, which makes it difficult to know the optimal way to manage multiple myeloma in this era of newer therapies.

For individuals who achieve a PR with induction therapy, Heather J. Landau, MD, suggests proceeding to stem cell transplant, with the consideration of stem cell mobilization by chemotherapy in individuals who have not had adequate bone marrow cytoreduction. It is important to build clinical trial data to understand what to do now, particularly with a novel agent, says Rafael Fonseca, MD. 

Most patients are achieving better than a PR with the newer drugs, states Noopur Raje, MD. For the time being, stem cells can still be collected and stored for later use at least in the younger population, suggests Raje. To further explore an optimal sequence for novel agents and transplant, a phase II study is assessing carfilzomib, lenalidomide, and dexamethasone before and after stem cell transplant for patients with newly diagnosed multiple myeloma (NCT01816971). This study will help shed light on a possible sequence, Raje suggests. 
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x